Format

Send to

Choose Destination
Case Rep Oncol Med. 2014;2014:940591. doi: 10.1155/2014/940591. Epub 2014 Apr 3.

Combination therapy of albumin-bound Paclitaxel and Carboplatin as first line therapy in a patient with ovarian cancer.

Author information

1
D.M.R.T, GVN Hospital, Trichy 620008, India ; GVN Institute of Oncology, 2nd Cross, Thillai Nagar, Trichy 620015, India.
2
D.M, Manipal Hospital, Bangalore 560017, India.
3
S.L Raheja Hospital, Mumbai 400016, India.

Abstract

BACKGROUND:

Ovarian cancer is the ninth most common cancer among women and causes more deaths than any other type of female reproductive cancer. Albumin-bound paclitaxel is known to increase intratumoral concentration of the paclitaxel by a receptor-mediated transport process across the endothelial cell wall, thereby breaching the blood/tumor interface. We present below three cases in which nab-paclitaxel based chemotherapy has been used in different settings for patients with ovarian cancer.

CASE PRESENTATION:

In the first case nab-paclitaxel was used along with carboplatin in adjuvant setting, in the second case, nab-paclitaxel was used along with carboplatin and bevacizumab as second line chemotherapy in a relapsed ovarian cancer case, and the third case delineates the use of nab-paclitaxel along with cisplatin as third line chemotherapy.

CONCLUSION:

In all the three scenarios, patients tolerated the chemotherapy well, as well as responding well to nab-paclitaxel based chemotherapy. The patients are currently on long-term follow-up and have been having an uneventful postchemotherapy.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center